iifl-logo

Alembic Pharmaceuticals Ltd Share Price

902.15
(0.59%)
May 8, 2025|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Equities

Futures

Option

  • Open891
  • Day's High906.7
  • 52 Wk High1,303.9
  • Prev. Close896.85
  • Day's Low885.6
  • 52 Wk Low 725.2
  • Turnover (lac)804.39
  • P/E35.81
  • Face Value2
  • Book Value275.33
  • EPS25.05
  • Mkt. Cap (Cr.)17,732.94
  • Div. Yield1.23
View All Historical Data
No Records Found

Alembic Pharmaceuticals Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

891

Prev. Close

896.85

Turnover(Lac.)

804.39

Day's High

906.7

Day's Low

885.6

52 Week's High

1,303.9

52 Week's Low

725.2

Book Value

275.33

Face Value

2

Mkt Cap (₹ Cr.)

17,732.94

P/E

35.81

EPS

25.05

Divi. Yield

1.23

Alembic Pharmaceuticals Ltd Corporate Action

9 May 2024

12:00 AM

Dividend

Dividend Amount: 11

Record Date: 15 Jul, 2024

arrow

21 Jun 2024

12:00 AM

AGM

Announcement Date: 21 Jun, 2024

arrow

18 Apr 2025

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

Alembic Pharmaceuticals Ltd NEWS AND UPDATE

Alembic Pharma Reports 17% Growth in Q4 Sales
7 May 2025|11:20 AM

EBITDA was up 9% at ₹286 crore, with EBITDA margin at 16% of total sales, reflecting operating efficiency.

Read More
Alembic Pharma Gets USFDA Nod for Carbamazepine 200 mg
17 Apr 2025|02:49 PM

The approved product is the generic equivalent of Tegretol Tablets 200 mg, which was initially developed by Novartis Pharmaceuticals Corporation.

Read More
Alembic Pharma Secures USFDA Approval for Pantoprazole Injection
1 Apr 2025|01:58 PM

This approval bolsters Alembic's portfolio in the United States market and reinforces its presence in injectable segment 

Read More
Alembic Pharma’s Vadodara Plant Gets VAI Status from US FDA
15 Feb 2025|12:00 PM

Following an inspection carried out from Nov 14-22 2024, the facility was cited as being ‘VAI’ (Voluntary Action Indicated).

Read More
Alembic Pharma reports 23% decline in Q3 net profit
4 Feb 2025|08:49 AM

EBITDA margin came in at 15.4% in the quarter under review as compared to 16.30% in the previous corresponding period.

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Alembic Pharmaceuticals Ltd SHAREHOLDING SNAPSHOT

09 May, 2025|06:17 PM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 0.52%

Foreign: 0.51%

Indian: 69.15%

Non-Promoter- 20.38%

Institutions: 20.37%

Non-Institutions: 9.95%

Custodian: 0.00%

Share Price

Alembic Pharmaceuticals Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Y/e 31 Mar( In .Cr)Mar-2024Mar-2023Mar-2022Mar-2021

Equity Capital

39.31

39.31

39.31

39.31

Preference Capital

0

0

0

0

Reserves

4,869.6

4,374.99

5,251.03

5,062.5

Net Worth

4,908.91

4,414.3

5,290.34

5,101.81

Minority Interest

View Balance Sheet
Y/e 31 Mar( In .Cr)Mar-2021Mar-2020Mar-2018Mar-2017

Revenue

5,051.44

4,132.55

2,945.26

2,985.9

yoy growth (%)

22.23

40.31

-1.36

-0.76

Raw materials

-1,297.91

-1,045.89

-892.73

-886.29

As % of sales

25.69

25.3

30.31

29.68

Employee costs

-948.27

-806.37

-582.72

-527.46

View Profit & Loss
Y/e 31 Mar( In .Cr)Mar-2021Mar-2020Mar-2018Mar-2017

Profit before tax

1,416.6

1,176.79

535.23

549.71

Depreciation

-152.6

-135.67

-101.76

-82.9

Tax paid

-241.21

-197.39

-113.25

-119.08

Working capital

-16.69

598.87

208.77

-67.37

Other operating items

View Cash Flow
Y/e 31 MarMar-2021Mar-2020Mar-2018Mar-2017

Growth matrix (%)

Revenue growth

22.23

40.31

-1.36

-0.76

Op profit growth

30.7

90.16

-0.1

-35.56

EBIT growth

18.91

123.64

-2.79

-39.74

Net profit growth

21.24

129.72

-2

-38.36

View Ratios
Particulars (Rupees in Crores.)Mar-2025Mar-2024Mar-2023Mar-2022Mar-2021

Gross Sales

6,672.08

6,228.63

5,652.62

5,305.79

5,393.13

Excise Duty

0

0

0

0

0

Net Sales

6,672.08

6,228.63

5,652.62

5,305.79

5,393.13

Other Operating Income

0

0

0

0

0

Other Income

56.3

28.31

2.74

55.74

87.29

Alembic Pharmaceuticals Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceutical Industries Ltd

SUNPHARMA

1,781.3

135.674,27,405.531,181.050.765,985.3398.33

Divis Laboratories Ltd

DIVISLAB

6,148

78.681,63,113.195940.492,297513.62

Cipla Ltd

CIPLA

1,508.8

26.181,21,868.91,438.150.864,134.87360.72

Torrent Pharmaceuticals Ltd

TORNTPHARM

3,291.1

61.041,11,340.164850.852,330222.38

Mankind Pharma Ltd

MANKIND

2,432.4

51.851,00,258.65416.3802,396.57334.17

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Alembic Pharmaceuticals Ltd

Management

Register Office

Registrar Office

Chairman & CEO

Chirayu R Amin

Director (Finance) & CFO

Rajkumar Baheti

Managing Director

Pranav Amin

Managing Director

Shaunak Amin

Independent Director

Archana Hingorani

Independent Director

Ashok Barat

Company Sec. & Compli. Officer

Manisha Saraf

Independent Director

Jai S Diwanji

Independent Director

Manish Kejriwal

Independent Director

Geeta Goradia

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Summary

Alembic Pharmaceuticals Limited manufactures and markets generic pharmaceutical products all over the world. The companys state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. The company is one of the leaders in branded generics in India. Alembic Pharmaceuticals Limited was incorporated on June 16, 2010 as a wholly owned subsidiary of Alembic Limited. The company is engaged in pharmaceuticals business. As per the Scheme of Arrangement, the Pharmaceutical Undertaking of Alembic Limited got demerged and transferred to the Company with effect from April 1, 2010. In April 2011, the company ceased to be a subsidiary of Alembic Ltd consequent to the allotment of 13,35,15,914 equity shares of Rs 2 each to the shareholders of Alembic Ltd as per the scheme of arrangement. The shareholding of Alembic Ltd in the company reduced from 100% to 29.18%. Thus, the company became an associate of Alembic Ltd.In September 2011, the equity shares of the company were listed on the Bombay Stock Exchange and National Stock Exchange. During 2012, Alembic and Breckenridge Announced Paragraph IV ANDA Litigation with Pfizer on Desvenlafaxine (Pristiq). The company enters into a product development and license agreement with Accu-Break Pharmaceuticals, Inc, USA. During 2013, the company got USFDA approval for its NDA - Desvenlafaxine Base Extended Release Tablets and also entered into an out-licensing agreement wit
Read More

Company FAQs

What is the Alembic Pharmaceuticals Ltd share price today?

The Alembic Pharmaceuticals Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹902.15 today.

What is the Market Cap of Alembic Pharmaceuticals Ltd?

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Alembic Pharmaceuticals Ltd is ₹17732.94 Cr. as of 08 May ‘25

What is the PE and PB ratio of Alembic Pharmaceuticals Ltd?

The PE and PB ratios of Alembic Pharmaceuticals Ltd is 35.81 and 3.39 as of 08 May ‘25

What is the 52 Week High and Low of Alembic Pharmaceuticals Ltd?

The 52-week high/low is the highest and lowest price at which a Alembic Pharmaceuticals Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Alembic Pharmaceuticals Ltd is ₹725.2 and ₹1303.9 as of 08 May ‘25

What is the CAGR of Alembic Pharmaceuticals Ltd?

Alembic Pharmaceuticals Ltd's CAGR for 5 Years at 2.26%, 3 Years at 7.32%, 1 Year at -12.17%, 6 Month at -16.95%, 3 Month at 1.15% and 1 Month at 6.14%.

What is the shareholding pattern of Alembic Pharmaceuticals Ltd?

The shareholding pattern of Alembic Pharmaceuticals Ltd is as follows:
Promoters - 69.67 %
Institutions - 20.37 %
Public - 9.96 %

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.